Melatonin: Why 0.5 mg Often Beats 10 mg for Sleep

Walk down a US pharmacy sleep aisle and the labels shout 5 mg, 10 mg, even 12 mg. The research points the other way: in controlled trials, doses as low as 0.3–0.5 mg — a tenth of a typical tablet — matched or beat megadoses at shortening the time it takes to fall asleep, with less next-day fog. More melatonin does not mean more sleep.

The evidence on dose

Melatonin is a hormone, not a classic sedative. Your pineal gland starts releasing it about two hours after darkness falls, and healthy nighttime blood peaks sit at roughly 80–150 pg/mL. A 0.5 mg oral dose reproduces those physiological levels. A 10 mg dose pushes concentrations tens of times above the natural range — and keeps them there for hours.

That overshoot matters because melatonin works through receptors that saturate at low concentrations. Research from MIT's clinical research center found that 0.3 mg improved sleep in middle-aged and older adults, while 3 mg and 10 mg lost effectiveness — a classic saturation curve. Once the receptors are full, extra hormone has nowhere useful to go.

The meta-analytic numbers are modest and honest. A 2013 meta-analysis of randomized placebo-controlled trials found melatonin shortened sleep-onset latency by about 7 minutes and extended total sleep time by about 8 minutes versus placebo. Real, measurable — not dramatic.

Usage has exploded anyway. NHANES survey data published in JAMA showed the share of US adults taking melatonin rose from 0.4% in 1999–2000 to 2.1% in 2017–2018, before the pandemic bump. Most products are formulated at 1–10 mg — far above the studied physiological range.

What's actually in the bottle

In the United States, melatonin is sold as a dietary supplement, not an FDA-approved drug, so content control is loose. A 2017 Canadian analysis of 31 supplements found actual melatonin ranged from 83% below to 478% above the label claim, with lot-to-lot variation of up to 465% in some brands — and 26% of products also contained serotonin. A "10 mg" gummy is not a precise instrument.

Regulation differs across markets: in the UK melatonin is prescription-only; Australia restricts pharmacy supply of 2 mg modified-release tablets to adults 55 and over; Canada licenses it as a natural health product. But the low-dose logic holds everywhere, because it comes from the pharmacology, not the label.

Why it matters

If more isn't better, a megadose habit costs money and buys side effects. The most commonly reported melatonin adverse events are daytime drowsiness, headache, dizziness and unusually vivid dreams — and all of them scale with dose. NIH's Office of Dietary Supplements also flags potential interactions with anticoagulants, diabetes medications and immunosuppressants. If you drive or operate machinery the morning after 10 mg, you are running an uncontrolled experiment on your own alertness.

Expectations need calibrating too. A 7-minute improvement in sleep onset will not fix chronic insomnia — cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment there. Where melatonin genuinely shines is timing: jet lag, delayed sleep-phase patterns and shift transitions. And in those circadian uses, the phase-response studies that mapped how melatonin shifts the body clock used 0.5 mg, finding that higher doses added little extra shifting power.

The honest counterpoint

The strongest objection: the American Academy of Sleep Medicine's 2017 clinical practice guideline recommends that clinicians not prescribe melatonin for insomnia at all, judging the evidence weak. Defenders of higher doses also note that several positive trials used 2–10 mg, and some researchers argue older adults — who produce less endogenous melatonin — may tolerate and need more.

That critique of evidence quality is fair. But it does not rescue the megadose. Even trials using higher amounts show no additional sleep-onset benefit above roughly 1 mg, while adverse effects rise with dose. And the 2 mg prescription product used in the UK and Australia is modified-release — a deliberately different pharmacology from a 10 mg fast-release gummy, not support for it.

Our editorial position, labeled as opinion: starting at 0.5 mg is the rational first test, and adjusting the timing — not the dose — is the correct second move if it underperforms.

One more safety data point: CDC surveillance reported a 530% rise in pediatric melatonin ingestions reported to US poison centers between 2012 and 2021, with emergency visits and hospitalizations following. Megadoses in the home medicine cabinet are part of that risk picture.

How to try the low-dose approach

• Start with 0.5 mg, taken 30–60 minutes before your target bedtime — not while scrolling in bed.
• If your goal is shifting your body clock (jet lag, delayed sleep phase), timing is the lever: take it near local bedtime at your destination.
• Dim the lights first; bright evening screens suppress your own melatonin release and undercut the dose you just took.
• Choose brands with third-party verification (USP or NSF), given the documented label variability in supplements.
• Give it a defined window — two weeks — then reassess. Persistent insomnia belongs with a clinician, and CBT-I outperforms any pill on the shelf.

Melatonin is not a stronger-works-better drug. It is a darkness signal, and the body reads it fluently at whisper volume. Small doses speak that language. Megadoses mostly shout — and shouting rarely puts anyone to sleep faster.